We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+22.98%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$2.69B
AUM Growth
+$481M
Cap. Flow
+$129M
Cap. Flow %
4.79%
Top 10 Hldgs %
44.27%
Holding
113
New
25
Increased
16
Reduced
30
Closed
12

Top Buys

Rank Stock Value
1
KO icon
Coca-Cola
KO
+$32.8M
2
AAPL icon
Apple
AAPL
+$32.1M
3
AVBP icon
ArriVent BioPharma
AVBP
+$31.5M
4
ARGX icon
argenx
ARGX
+$26.4M
5
CRH icon
CRH
CRH
+$25.7M

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$55.4M
2
RPRX icon
Royalty Pharma
RPRX
+$48.3M
3
LVS icon
Las Vegas Sands
LVS
+$36.3M
4
MSFT icon
Microsoft
MSFT
+$33.4M
5
TERN
Terns Pharmaceuticals
TERN
+$29.2M

Sector Composition

Rank Sector Weight
1 Healthcare 57.97%
2 Technology 7.85%
3 Communication Services 7.05%
4 Consumer Discretionary 4.46%
5 Financials 3.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$235M 8.74%
+450,000
New +$224M
BHVN icon
2
Biohaven
BHVN
$2.16B
$219M 8.13%
4,003,046
-569,790
-12% -$28.2M
KURA icon
3
Kura Oncology
KURA
$922M
$151M 5.6%
7,069,627
+123,397
+2% +$2.4M
ACLX
4
DELISTED
Arcellx
ACLX
$109M 4.04%
1,562,354
-873,620
-36% -$55.4M
QQQ icon
5
PUT
Invesco QQQ Trust
QQQ
$455B
$86.6M 3.22%
+195,000
New +$83.6M
META icon
6
Meta Platforms (Facebook)
META
$1.51T
$84.3M 3.13%
173,605
-46,578
-21% -$20.8M
RARE icon
7
Ultragenyx Pharmaceutical
RARE
$2.65B
$78.3M 2.91%
1,676,811
-449,495
-21% -$21.2M
ARQT icon
8
Arcutis Biotherapeutics
ARQT
$3.42B
$78.1M 2.9%
7,877,297
-595,804
-7% -$4.45M
EYPT icon
9
EyePoint Inc
EYPT
$1.02B
$77.8M 2.89%
3,763,888
-292,959
-7% -$7.25M
ETNB
10
DELISTED
89bio
ETNB
$73.3M 2.72%
6,298,004
+1,409,570
+29% +$15.6M
RPRX icon
11
Royalty Pharma
RPRX
$26.1B
$68.3M 2.54%
2,250,361
-1,637,341
-42% -$48.3M
ITCI
12
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$66.4M 2.47%
959,198
-206,750
-18% -$14.2M
AMZN icon
13
Amazon
AMZN
$2.5T
$64.4M 2.39%
356,962
-11,127
-3% -$1.86M
AMD icon
14
Advanced Micro Devices
AMD
$851B
$61.7M 2.29%
341,699
+8,231
+2% +$1.44M
INSM icon
15
Insmed
INSM
$23.2B
$54.9M 2.04%
2,023,000
-661,487
-25% -$18.5M
CI icon
16
Cigna
CI
$76.6B
$49.8M 1.85%
137,139
+40,839
+42% +$13.4M
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
$49.7M 1.85%
4,192,005
+1,508,000
+56% +$20.1M
VZ icon
18
Verizon
VZ
$194B
$49.5M 1.84%
1,179,452
+462,602
+65% +$18.7M
ARGX icon
19
argenx
ARGX
$57.4B
$48M 1.78%
121,900
+68,200
+127% +$26.4M
MRNS
20
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$46.2M 1.72%
5,108,520
-237,599
-4% -$2.31M
GS icon
21
Goldman Sachs
GS
$313B
$45.9M 1.7%
109,890
-420
-0.4% -$163K
TSM icon
22
TSMC
TSM
$2.09T
$44.8M 1.66%
329,352
-58,880
-15% -$7.31M
T icon
23
AT&T
T
$165B
$42.2M 1.57%
2,398,619
+1,178,539
+97% +$20.1M
APO icon
24
Apollo Global Management
APO
$70.7B
$41.7M 1.55%
370,636
-170,184
-31% -$18M
FERG icon
25
Ferguson
FERG
$44.7B
$37M 1.37%
169,280
-6,810
-4% -$1.36M
1
2 3 4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return

Suvretta Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Suvretta Capital Management held 113 positions worth $2.69B, up 22% from $2.21B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Suvretta Capital Management deployed $129M of net new capital in Q1 2024, opening 25 new positions and adding to 16 existing holdings. Its largest new stake was Coca-Cola: 546,500 shares worth $33.4M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 68% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Arcellx, an estimated $55.4M trimmed.

  • Suvretta Capital Management's largest Q1 2024 buy was Coca-Cola: 546,500 shares worth $33.4M.
  • Suvretta Capital Management added most to argenx in Q1 2024, an estimated $26.4M increase.
  • Suvretta Capital Management's biggest Q1 2024 reduction was Arcellx, cutting an estimated $55.4M.
  • Suvretta Capital Management fully exited Las Vegas Sands in Q1 2024, selling an estimated $36.3M.
  • Suvretta Capital Management's ten largest holdings make up 44% of its $2.69B portfolio in Q1 2024.
  • Suvretta Capital Management opened 25 new positions and closed 12 in Q1 2024.
  • Suvretta Capital Management's portfolio value rose 22% quarter-over-quarter to $2.69B.

Based on Suvretta Capital Management's 13F filing for Q1 2024, filed 15 May 2024.